biosimilars
‘A’ flagging has Medicines Australia concerned
Medicines Australia has expressed concern about the PBAC’s recommendation that pharmacists be allowed to substitute the biosimilars in place of biologic medicines prescribed by a patient’s doctor. “The so-called ‘a-flagging’ …
Biosimilars: PBAC ‘a’ flags infliximab
The PBAC today recommended that Inflectra (infliximab), the first monoclonal antibody ‘mAb’ biosimilar registered in Australia, be added to the Pharmaceutical Benefits Scheme. The recommendation is the first step towards …
GBMA welcomes infliximab biosimilar listing
The Generic and Biosimilar Medicines Association has welcomed the approval of biosimilar infliximab, Inflectra. Inflectra is the first biosimilar infliximab to be approved in Australia, providing an alternative, affordable treatment …
ACCC okays Pfizer’s Hospira acquisition
The Australian Competition and Consumer Commission has announced that it will not oppose Pfizer Inc’s proposed $US17 billion acquisition of Hospira Inc. “Pfizer and Hospira are also the two largest …
GMiA becomes Generic and Biosimilar Medicines Association
From today, the Generic Medicines Industry Association will be known as the Generic and Biosimilar Medicines Association. After patents expire on brand name medicines, affordable generic and biosimilar medicines deliver …
Consumers Health Forum worried on biosimilars
The Consumers Health Forum has expressed its concerns about the issue of substitution of biological medicines with biosimilars, at a meeting called by the Pharmaceutical Benefits Advisory Committee. CEO of …
Ley abandons strategic agreement, Medicines Australia disappointed
Medicines Australia says it is “extremely disappointed” with a last-minute decision by Health Minister Sussan Ley to abandon a Strategic Agreement, which it says casts a shadow over the future …
Don’t give pharmacists power over biosimilars: Australian Rheumatology Association
The Australian Rheumatology Association has expressed concerns about risks to patient safety it says could follow from measures on biosimilars going through the Senate today as part of the wider …
PBAC moves to reassure on biosimilars
The PBAC has issued a statement intending to reassure the public about the safety of biosimilar copies of biologic drugs, in a bid to stamp out “misinformation” which could slow …
GMiA welcomes ‘a’ flagging of biosimilars
The Generic Medicines Industry Association has welcomed the PBAC’s decision to consider “a” flagging of biosimilars, and to list biosimilar insulin (Basaglar) on the PBS. Basaglar is the first biosimilar …